BLUF is in public beta. Automated sourcing and summaries by the BLUF engine, monitored by our team. Summaries may contain errors — verify important details at the source. Not medical, legal or financial advice. Public beta — automated summaries may contain errors. Full disclaimer
FDA rejects Summit Therapeutics’ lung cancer treatment ivonescimab
3 OUTLETS UNITED STATESONGOING
NOT MEDICAL ADVICE
This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
BLUF
The FDA has rejected ivonescimab, a lung cancer treatment developed by U.S. biotech Summit Therapeutics and Chinese drugmaker Akeso, according to STAT. The drug is not approved in the United States.
WHAT IS VERIFIED — AND WHAT IS NOT
Source coverage is not proof of every claim. Confirmed means direct support from an official record; corroborated means matching reporting; reported means attributed but not independently verified here. Disputed details remain unresolved.
CORROBORATED
The FDA rejected ivonescimab, a lung cancer treatment developed by Summit Therapeutics and Akeso.
HOW THIS BRIEF WAS MADE 3 outlets: 1 national · 1 international · 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections
CONFIDENCE: MODERATE · SOURCE GRADE B2Coverage from 3 independent outlets of 3 kinds; no official record is among BLUF's sources yet; officials may be quoted in the reporting. Coverage breadth does not verify every claim; see claim-level sources. What B2 means
Why it matters
The rejection means ivonescimab is not available as an approved treatment in the United States.
What happens next
No next step or update time has been announced in the available reporting.